赛托生物业务进展与股价震荡，机构观点谨慎

Group 1 - The core focus of the company is on business development and qualification certification, particularly in high-end respiratory active pharmaceutical ingredients [1] - The company has a strategy to adjust pricing based on market conditions to expand channels and increase market share [1] - The subsidiary, Sry Pharmaceutical, has received a high-tech enterprise certificate valid for three years, indicating the company's strengthening in innovation and technology capabilities [1] Group 2 - The stock price of the company has shown fluctuations over the past week, ranging from 14.81 yuan to 14.99 yuan, with a total change of 1.35% and a volatility of 3.72% [2] - Trading volume and turnover rate have remained active, with a single-day increase of 1.69% on February 9, followed by a decrease of 0.66% on February 11 [2] - The current stock price is close to the 20-day moving average, indicating some short-term pressure in the technical analysis [2] Group 3 - Institutional interest in the company is moderate, with a neutral sentiment prevailing in public opinion [3] - Two institutions have provided profit forecasts, expecting a net profit growth of 29.12% in 2025 and 17.67% in 2026, suggesting continued revenue expansion [3] - Institutional ratings are neutral with no clear target price, and the low proportion of institutional holdings reflects market caution regarding the company's short-term outlook [3]